The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
J. H. Strickler
No relevant relationships to disclose
A. L. Cohn
No relevant relationships to disclose
C. Arrowood
No relevant relationships to disclose
S. Haley
No relevant relationships to disclose
M. Morse
Consultant or Advisory Role - Genentech
Honoraria - Bristol-Myers Squibb; Genentech
H. Uronis
Research Funding - Bristol-Myers Squibb
G. C. Blobe
Consultant or Advisory Role - Roche
Honoraria - Roche
S. D. Hsu
No relevant relationships to disclose
Y. Zafar
Honoraria - Genentech
H. Hurwitz
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech; Roche
Honoraria - Roche
Research Funding - Bristol-Myers Squibb; Roche